Table 5 Answers to questions on professional practices, globally and by professional group

Number of cases seen, % (n)

 1–5

14.6 (7/48)

75.5 (40/53)

 < 0.001* (χ² = 46.2, df = 2)

 6–10

8.3 (4/48)

13.2 (7/53)

 11–50

39.6 (19/48)

11.3 (6/53)

  > 50

37.5 (18/48)

Type of sample used for diagnosis (0–3)^a

 Bone marrow biopsy/aspirate

0.49

2.22

 < 0.001* (U = 298.0)

 Liver biopsy/aspirate

0.85

 Lymph node biopsy/aspirate

1.00

1.12

0.485 (U = 1129.5)

 Spleen biopsy/aspirate

0.20

0.43

0.074 (U = 1005.5)

 Skin

0.78

 Blood

2.84

2.18

 < 0.001* (U = 808.5)

Type of laboratory exam used for diagnosis (0–3)^a

 Culture

0.24

0.96

 < 0.001* (U = 722.0)

 Microscopy of smear/histology

0.78

2.08

 < 0.001* (U = 501.5)

 PCR

1.32

2.19

 < 0.001* (U = 647.5)

 Quantitative serology

2.53

1.77

 < 0.001* (U = 623.5)

 Qualitative serology

2.23

Drug used for treatment (0–4)^b

 Miltefosine

1.75

1.11

 < 0.001* (U = 824.5)

 MA/Pentavalent antimonials

2.02

0.80

 < 0.001* (U = 536.0)

 Allopurinol

3.30

NA

 Allopurinol + MA

2.26

NA

 Allopurinol + miltefosine

1.90

NA

 Liposomal amphotericin B

NA

3.32

 Paromomycin

NA

0.26

 Amphotericin B deoxycholate

NA

0.24

 Pentamidine

NA

0.12

Recommended individual protective measures to patients, %, (n)

 Often/always

93.0 (53/57)

8.1 (8/99)

 < 0.001* (χ² = 109.5, df = 1)